

Edgar Filing: CARDIOPENESIS CORP /CA - Form NT 10-K

CARDIOGENESIS CORP /CA
Form NT 10-K
March 29, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12B-25

NOTIFICATION OF LATE FILING

OMB APPROVAL

OMB Number:
Expires:
Estimated average burden
hours per response... 2.50

SEC FILE NUMBER
000-28288

CUSIP NUMBER
278849-10-4

(Check One): Form 10-K Form 20-F Form 11-K Form 10-Q Form N-SAR

For Period Ended: December 31, 2001

- Transition Report on Form 10-K
 - Transition Report on Form 20-F
 - Transition Report on Form 11-K
 - Transition Report on Form 10-Q
 - Transition Report on Form N-SAR
- For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

N/A

PART I -- REGISTRANT INFORMATION

Full Name of Registrant

CARDIOGENESIS CORPORATION

Former Name if Applicable

ECLIPSE SURGICAL TECHNOLOGIES, INC

Address of Principal Executive Office (Street and Number)

26632 Towne Center Dr., Suite 320

City, State and Zip Code

Edgar Filing: CARIOGENESIS CORP /CA - Form NT 10-K

Foothill Ranch, CA 92610

PART II -- RULES 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant cannot file its Annual Report on Form 10-K within the prescribed time period without unreasonable expense and effort and will require a fifteen (15) day extension due to the following reasons:

- (1) Effective January 15, 2002, the Registrant changed Chief Financial Officers;
- (2) As part of the Registrant's previously announced July 2001 and January 2002 restructurings, there was a significant reduction in accounting personnel; and
- (3) The Registrant recently as of July 2001 relocated its headquarters from Sunnyvale, California to Foothill Ranch, California.

(ATTACH EXTRA SHEETS IF NEEDED)
SEC 1344 (6/94)

POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

PART IV -- OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this

Edgar Filing: CARDIOGENESIS CORP /CA - Form NT 10-K

notification

Darrell F. Eckstein	(714)	649-5000
-----	-----	-----
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). [X] Yes [] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

CARDIOGENESIS CORPORATION

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date	March 29, 2002	By	/s/ Darrell F. Eckstein
-----	-----	-----	-----
			Vice President and Interim Chief Financial Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

-----ATTENTION-----

Intentional misstatements or omissions of fact constitute Federal
Criminal Violations (See 18 U.S.C. 1001).
